Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nicotinamide Riboside Supplementation in Allogeneic HCT
NCT04332341Phase 1Recruiting
- Sponsor
- Case Comprehensive Cancer Center
- Start
- May 2020
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nicotinamide riboside, sponsored by Case Comprehensive Cancer Center. Primary endpoints: Percent of participants who receive >75% of scheduled doses at Day 7, Percent of participants who receive >75% of scheduled doses at Day 14 and 4 more. Started May 2020; status: recruiting.
02
Drugs
nicotinamide riboside
Beyond the preview
Go deeper on NCT04332341.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04332341.